SANOFI AVENTIS R&D

The project concerns the design, construction or modernisation, and the equipment of several buildings providing facilities for pharmacological research, product development facilities and office space in Europe.

The project aims at regrouping and reorganizing the promoter’s R&D activities in order to optimize the use of premises and equipments and facilitate the synergies between different therapeutic areas. It concerns the design, construction or modernisation, and the equipment of several buildings providing facilities for pharmacological research and office space in Europe. The facilities will be located in France, Germany, United Kingdom, Spain and Italy, mostly in the promoter’s existing R&D sites.

The sub-projects fall under Annex II of the directive EU/97/11 amended by Directive 2003/35/EC on Environmental Impact Assessment (EIA). The determination made by the competent authorities for requesting (or not) an EIA on the basis of Annex III of the Directive and actual/possible significant impacts on protected flora and fauna (Habitats’ and Birds’ Directives) has been verified during project appraisal.

The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed have been verified during appraisal.